 |
BioWorld-International-2006-12-20
Genmab Licenses HuMax-CD20 To GSK In Potential $2.1B Deal
Genmab Licenses HuMax-CD20 To GSK In Potential $2.1B Deal
Billing it as the biotechnology industry's biggest ever drug deal, Genmab A/S licensed the human monoclonal antibody HuMax-CD20 (ofatumumab) to GlaxoSmithKline plc in a transaction with a total potential value exceeding DKK12 billion (US$2.1 billion) and a guaranteed amount of about DKK2.6 billion.
(BioWorld International)